Table 2 Comparison of baseline characteristics among common U2AF1 mutations (N = 143).
Variables | S34F (n = 97) | Q157P (n = 46) | P value |
|---|---|---|---|
Age | 71 [25–92] | 71 [53–92] | 0.95 |
Age ≥70 years | 56 (60) | 26 (56.5) | 0.85 |
High-risk myeloid neoplasm | 26 (27) | 13 (28) | >0.99 |
t-AML | 17 (18) | 7 (16) | 0.81 |
CCUS | 16 (16) | 2 (4) | 0.77 |
MDS | 55 (57) | 31 (67) | 0.27 |
MDS/AML | 10 (10) | 4 (9) | 0.77 |
AML | 16 (17) | 9 (20) | 0.81 |
Hemoglobin (g/dl) | 9.3 [6.4–13.3] | 8.3 [5.8–13.1] | 0.82 |
≤ 10.0 | 66 (69) | 37 (80) | 0.16 |
≤ 8.0 | 19 (20) | 12 (26) | 0.51 |
WBC (109/L) | 2.4 [0.5–10.3] | 2.9 [0.9–60] | 0.23 |
Platelet (109/L) | 93 [11–309] | 83 [12–542] | 0.72 |
≤ 100.0 | 51 (54) | 24 (54.4) | >0.99 |
≤ 50.0 | 19 (20) | 14 (32) | 0.19 |
BM blast (%) | 3 [0–83] | 3.5 [0–90] | 0.91 |
U2AF1 VAF (%) | 33 [2–51] | 38 [11–46] | 0.37 |
CG abnormality | 68 (70) | 28 (62) | 0.05 |
Co-mutation | 71 (74) | 42 (91) | 0.01 |
ASXL1 | 27 (28) | 23 (50) | 0.01 |
BCOR | 22 (23) | 0 | 0.04 |
RUNX1 | 11 (12) | 9 (19) | 0.46 |
TET2 | 14 (15) | 5 (11) | 0.60 |
DNMT3A | 12 (12) | 4 (9) | 0.58 |
RAS | 8 (8) | 2 (4) | 0.50 |
TP53 | 4 (4) | 7 (15) | 0.03 |
JAK2 | 4 (4) | 5 (11) | 0.27 |
SETBP1 | 5 (5) | 4 (9) | 0.47 |
NPM1 | 1 (1) | 0 | >0.99 |
FLT3 ITD | 2 (2) | 0 | 0.55 |
Two or more co-mutations | 45 (47) | 34 (73) | 0.02 |
MDS patients progressing to AML | 20/67 (30) | 15/29 (52) | 0.51 |
Treatment in high-risk myeloid neoplasm | |||
3 + 7 | 14 (20) | 4 (13) | 0.41 |
HMA | 41 (58) | 15 (33) | 0.09 |
HMA plus venetoclax | 4 (5.5) | 5 (16) | 0.72 |
Complete remission | 19 (19.5) | 7 (15) | >0.99 |
Allo-HCT | 18 (19) | 9 (21) | 0.81 |
